Sodium hyaluronate - Lantibio

Drug Profile

Sodium hyaluronate - Lantibio

Alternative Names: Hyaluronan - TRB Chemedica; Hyaluronic acid - Lantibio; Rejena; SVS-20; Vismed®

Latest Information Update: 13 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TRB Chemedica
  • Developer Horus Pharma; Lantibio
  • Class Adjuvants; Antirheumatics; Eye disorder therapies; Glycosaminoglycans; Urologics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Dry eyes

Most Recent Events

  • 20 Jun 2018 Phase-III clinical trials in Dry eyes in United Kingdom (Topical) (ISRCTN40779210)
  • 13 May 2014 Discontinued - Preregistration for Dry eyes in USA (Topical)
  • 08 Apr 2011 Novartis completes acquisition of Alcon
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top